Actively Recruiting
Safety Evaluation of Enfortumab Vedotin in Indian Adults with Advanced or Metastatic Urothelial Cancer Receiving Infusions
Led by Astellas Pharma Global Development, Inc. · Updated on 2026-08-21
100
Participants Needed
15
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating enfortumab vedotin in Indian adults with advanced or metastatic urothelial cancer, a type of bladder lining cancer that has spread. This study aims to confirm the safety of this treatment in this specific population. The trial is a phase 4, open-label, single-arm study focusing on adults who have previously received other cancer treatments including platinum-containing regimens and checkpoint inhibitors. Participants receive enfortumab vedotin via intravenous infusion on days 1, 8, and 15 of each 28-day cycle, with three infusions per cycle. The treatment is given slowly through a vein. All participants receive this drug as there is no comparison group. The study includes multiple cycles of treatment depending on participant response and tolerance. During the study, participants will visit the clinic several times for health checks, laboratory tests, vital sign monitoring, electrocardiograms, and assessments of their performance status. Researchers will measure adverse events, laboratory abnormalities, and response rates to treatment over periods ranging from 6.5 months to 34 months. Participants are also monitored for safety throughout the treatment and follow-up phases.
CONDITIONS
Brief Title
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Research Team
A
Astellas Pharma Global Development, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here